David Gyllenberg1, Andre Sourander2, Heljä-Marja Surcel3, Susanna Hinkka-Yli-Salomäki4, Ian W McKeague5, Alan S Brown6. 1. Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York State Psychiatric Institute, New York, New York; Department of Child Psychiatry, Faculty of Medicine, University of Turku. Electronic address: david.gyllenberg@utu.fi. 2. Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York State Psychiatric Institute, New York, New York; Department of Child Psychiatry, Faculty of Medicine, University of Turku; Department of Child Psychiatry, Turku University Hospital, Turku. 3. National Institute for Health and Welfare, Oulu, Finland. 4. Department of Child Psychiatry, Faculty of Medicine, University of Turku. 5. Department of Biostatistics, Columbia University Mailman School of Public Health, New York, New York. 6. Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York State Psychiatric Institute, New York, New York; Department of Epidemiology, Columbia University Mailman School of Public Health, New York, New York.
Abstract
BACKGROUND: Evidence from animal and human studies indicates that thyroid hormone deficiency during early gestation alters brain development. As schizophrenia is associated with prenatal brain insults and premorbid cognitive deficits, we tested the a priori hypothesis that serologically defined maternal thyroid deficiency during early gestation to mid-gestation is associated with schizophrenia in offspring. METHODS: The investigation is based on the Finnish Prenatal Study of Schizophrenia, a nested case-control study that included archived maternal sera from virtually all pregnancies since 1983 (N = >1 million). We identified all offspring in the cohort with a diagnosis of schizophrenia based on the national inpatient and outpatient register and matched them on sex, date of birth, and residence in Finland at time of onset of the case to comparison subjects (1:1) from the cohort. Maternal sera of 1010 case-control pairs were assessed for free thyroxine, and sera of 948 case-control pairs were assessed for thyroid-stimulating hormone. RESULTS: Maternal hypothyroxinemia (free thyroxine ≤10th percentile, normal thyroid-stimulating hormone) was associated with an increased odds of schizophrenia (odds ratio = 1.75, 95% confidence interval = 1.22-2.50, p = .002). When adjusted for maternal psychiatric history, province of birth, and maternal smoking during pregnancy, the association remained significant (odds ratio = 1.70, 95% confidence interval = 1.13-2.55, p = .010). CONCLUSIONS: In a large, national birth cohort, prospectively documented hypothyroxinemia during early gestation to mid-gestation was associated with increased odds of schizophrenia in offspring. This information can inform translational studies of maternal hypothyroxinemia examining molecular and cellular deviations relevant to schizophrenia.
BACKGROUND: Evidence from animal and human studies indicates that thyroid hormone deficiency during early gestation alters brain development. As schizophrenia is associated with prenatal brain insults and premorbid cognitive deficits, we tested the a priori hypothesis that serologically defined maternal thyroid deficiency during early gestation to mid-gestation is associated with schizophrenia in offspring. METHODS: The investigation is based on the Finnish Prenatal Study of Schizophrenia, a nested case-control study that included archived maternal sera from virtually all pregnancies since 1983 (N = >1 million). We identified all offspring in the cohort with a diagnosis of schizophrenia based on the national inpatient and outpatient register and matched them on sex, date of birth, and residence in Finland at time of onset of the case to comparison subjects (1:1) from the cohort. Maternal sera of 1010 case-control pairs were assessed for free thyroxine, and sera of 948 case-control pairs were assessed for thyroid-stimulating hormone. RESULTS:Maternal hypothyroxinemia (free thyroxine ≤10th percentile, normal thyroid-stimulating hormone) was associated with an increased odds of schizophrenia (odds ratio = 1.75, 95% confidence interval = 1.22-2.50, p = .002). When adjusted for maternal psychiatric history, province of birth, and maternal smoking during pregnancy, the association remained significant (odds ratio = 1.70, 95% confidence interval = 1.13-2.55, p = .010). CONCLUSIONS: In a large, national birth cohort, prospectively documented hypothyroxinemia during early gestation to mid-gestation was associated with increased odds of schizophrenia in offspring. This information can inform translational studies of maternal hypothyroxinemia examining molecular and cellular deviations relevant to schizophrenia.
Authors: Jens Henrichs; Jacoba J Bongers-Schokking; Jacqueline J Schenk; Akhgar Ghassabian; Henk G Schmidt; Theo J Visser; Herbert Hooijkaas; Sabine M P F de Muinck Keizer-Schrama; Albert Hofman; Vincent V W Jaddoe; Willy Visser; Eric A P Steegers; Frank C Verhulst; Yolanda B de Rijke; Henning Tiemeier Journal: J Clin Endocrinol Metab Date: 2010-06-09 Impact factor: 5.958
Authors: Sarah Canetta; Andre Sourander; Heljä-Marja Surcel; Susanna Hinkka-Yli-Salomäki; Jaana Leiviskä; Christoph Kellendonk; Ian W McKeague; Alan S Brown Journal: Am J Psychiatry Date: 2014-09 Impact factor: 18.112
Authors: Eva Ausó; Rosalía Lavado-Autric; Estela Cuevas; Francisco Escobar Del Rey; Gabriella Morreale De Escobar; Pere Berbel Journal: Endocrinology Date: 2004-04-15 Impact factor: 4.736
Authors: Gabriella Morreale de Escobar; María Jesús Obregón; Francisco Escobar del Rey Journal: Best Pract Res Clin Endocrinol Metab Date: 2004-06 Impact factor: 4.690
Authors: J Patrizia Stohn; M Elena Martinez; Donald L St Germain; Arturo Hernandez Journal: Psychoneuroendocrinology Date: 2019-09-18 Impact factor: 4.905
Authors: Marie-Therese J Strobl; Daniel Freeman; Jenica Patel; Ryan Poulsen; Christopher C Wendler; Scott A Rivkees; Jason E Coleman Journal: Cereb Cortex Date: 2017-05-01 Impact factor: 5.357
Authors: Louise Ramhøj; Terje Svingen; Karen Mandrup; Ulla Hass; Søren Peter Lund; Anne Marie Vinggaard; Karin Sørig Hougaard; Marta Axelstad Journal: PLoS One Date: 2022-07-19 Impact factor: 3.752
Authors: Tim I M Korevaar; Daan Nieboer; Peter H L T Bisschop; Mariette Goddijn; Marco Medici; Layal Chaker; Yolanda B de Rijke; Vincent W V Jaddoe; Theo J Visser; Ewout W Steyerberg; Henning Tiemeier; Tanja G Vrijkotte; Robin P Peeters Journal: Clin Endocrinol (Oxf) Date: 2016-08-15 Impact factor: 3.478